Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes
NCT ID: NCT01435980
Last Updated: 2015-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
60 participants
INTERVENTIONAL
2008-02-29
2016-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy
NCT02129985
Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function
NCT02584075
Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion
NCT01030952
Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia
NCT02685852
Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes
NCT04374578
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
60 Type 2 diabetes in our hospital will divide into 3 groups: group A (20 patients who give basal treatment), group B (20 patients who give basal and Exenatide treatment, group C（20 patients who give basal and Gastric Bypass treatment). The age, height, weight, blood glucose, glycosylated hemoglobin A1c（HbA1c）,homeostasis model assessment(HOMA-IR), lipid, blood pressure, course of disease, ejection fraction (EF), fractional shortening(FS), diameter of left ventricle in late diastolic stage(LVEDd), the thickness of the ventricular septa（IVSD) and the posterior wall of the right ventricle in late diastolic stage (LVPWd) will record respectively. Left ventricular mass index (LVMI), relative wall thickness (RWT) will calculate and High-sensitive C-reactive protein (HsCRP), adiponectin and Tumor necrosis factor-α（TNF-α） will detect as Baseline. After each group's treatment, Change from baseline of all indexes will record, Multifactor logistic regression will be analyzed the correlations between each positive indexes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
basal treatment
basal treatment
No interventions assigned to this group
Gastric Bypass
basal treatment and Gastric Bypass
Gastric Bypass
basal treatment and Gastric Bypass
Exenatide
basal treatment and Exenatide
Exenatide
basal treatment and Exenatide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gastric Bypass
basal treatment and Gastric Bypass
Exenatide
basal treatment and Exenatide
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. BMI32-34.9kg/m2, With Type 2 Diabetes, Insulin Therapy in Combination With Oral Administration of Drugs for 6 Months and HbA1c ≥ 7%;
3. Between the Ages of 18-60 Years;
4. Course of Type 2 Diabetes ≤ 5 Years;
5. ICA, IAA, GAD Are Negative , C-peptide Level is Not Less Than 0.3mg / L;
Exclusion Criteria
2. patients who had liver or renal failure
3. severe infections in patients and patients who had cerebrovascular disease
4. patients who had heart failure
5. fasting serum insulin or 2-hour postprandial serum insulin were lower than normal (\<20mmol / L)
6. course of diabetes\> 5 years or age\> 60 years or age \<18 years
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wu Qinan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wu Qinan
Third Military Medical University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
liang zi wen, doctor
Role: PRINCIPAL_INVESTIGATOR
Third Military Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Endocrine Department, the south west Hospital of the Third Military Medical University
Chongqing, Chongqing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
the south west Hospital2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.